J&J hands Ar­row­head a plum $3.7B deal for hep B-plus 3 — cor­ralling a pos­si­ble game-chang­ing RNAi drug

Two years af­ter Ar­row­head Phar­ma­ceu­ti­cals $AR­WR con­ced­ed that a sub­stan­tial seg­ment of their RNAi pipeline was hope­less­ly com­pro­mised and had to be jet­ti­soned, crip­pling their …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER